New ‘Reaxys’ Solution Improves Workflow Quality and Efficiency for Chemists
Frankfurt, Germany, 26 January 2009 – Elsevier, the leading publisher of scientific, medical and technical products and services, today introduced Reaxys, a new workflow solution for synthetic chemists. Reaxys is based on data from Elsevier’s industry leading chemistry databases (CrossFire Beilstein, CrossFire Gmelin and Patent Chemistry Database) now merged together to provide harmonized content, additional functionalities and a redesigned interface to help improve R&D efficiency. Reaxys also contains new unique features including a synthesis planner and advanced results handling to help scientists gather relevant information more efficiently.
“Scientists, both in academia and industry, are under increasing pressure to deliver more and better results in a shorter time and make research decisions faster” said Mark van Mierle, managing director for Elsevier Information Systems. “Reaxys now gives them a tool to quickly create an overview of the of synthesis design options available for their work, research and quickly identify and select the most appropriate. By integrating chemical reaction and substance data from trusted sources with a synthesis design process, customers can accelerate early phase discovery.”
• Workflow and decision making support for synthesis design and planning, e.g. by comparing alternative synthesis routes and selecting the most relevant paths;
• Quick access to key data by displaying results in a unique tabulated overview of the most important information;
• Convenient and flexible output of data in most common formats.
Reaxys has been developed with input and advice from development partners from corporate and academic research institutions around the world. In addition, the web interface has been designed by experts in human-computer interaction. The look and feel has been streamlined to make searching easier and provide a clear visualization of the results.
The result is a solution that goes beyond retrieving data. Search results reflect how chemists think and work, helping their workflow move seamlessly from initial search, recognition of possible starting materials and their properties and through planning a strategy for the synthesis of a new compound to proposing a detailed synthetic route. Most compounds in Reaxys can be identified by their CAS Registry Numbers®.
Migrating from Crossfire to Reaxys
Reaxys is available today and existing CrossFire customers may use Reaxys in parallel for an interim period. Elsevier offers full training and helpdesk support for new customers as well as guidance for the migration from CrossFire to the new platform. For the time being all CrossFire products as well as the Commander interface will be fully supported.
Select customers have been evaluating Reaxys throughout its development and have provided positive feedback. Elsevier will continue to engage with the chemistry community in future product development. For more information, visit www.info.reaxys.com.
Reaxys™ and CrossFire Beilstein are owned and protected by Elsevier Properties SA and used under license.
More about the addition of CAS Registry Numbers® can be found in a recent agreement between CAS (Chemical Abstract Service) and Elsevier: http://www.info.reaxys.com/press_room.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence,and ClinicalKey—and publishes over 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
+1 212 462 1912